The Pharma Data

JANUARY 11, 2021

a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.

Licensing 52

Licensing Licensing Therapies Engineering 52

The Pharma Data

JUNE 26, 2021

Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine. The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus. JUNE 22 , 2021. We look forward to sharing initial results by year-end. ”. “

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

AUGUST 6, 2020

We pointed out last week that China was a notable missing element in AstraZeneca’s COVID-19 vaccine strategy, despite being the drugmaker’s second-largest market. The pair will also explore the possibility of producing the vaccine for other markets. The vaccine was moved into phase 2/3 in May. That has changed.

Vaccine 52

Vaccine Licensing Licensing Immune Response 52

The Pharma Data

MARCH 11, 2021

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the start of the Phase 1/2 clinical trial for MRT5500, an mRNA vaccine candidate against SARS-CoV-2, the virus that causes COVID-19.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

AUGUST 28, 2020

The government plans to train up an army of health professionals to be ready to give the coronavirus vaccine, if and when one is shown to work. This could include pharmacists, who already deliver flu vaccines, midwives and physiotherapists. But a vaccine is not expected to be ready before Christmas. Source link.

Vaccine 52

Vaccine Immune Response Nurses Government 52

The Pharma Data

SEPTEMBER 4, 2020

Dr Moncef Slaoui, the leading doctor involved with Operation Warp Speed, has said it is unlikely a vaccine for the US will be ready by November. . But Slaoui did say that he believes a vaccine will be available by the end of the year, and could possibly vaccinate between 20 and 25 million people.

Doctors 52

Doctors Vaccine Licensing Licensing 52

The Pharma Data

NOVEMBER 17, 2021

AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the last 11 months. 2) From the body of evidence in clinical trials and real-world data, the vaccine has been shown to have an acceptable safety profile.(3,4,5,6,7).

Vaccine 52

Vaccine Clinical Trials Virus Licensing 52

The Pharma Data

JANUARY 22, 2021

As research developments into RNA vaccines help scientists accelerate drug candidates to arm the immune system against coronavirus, Pharma IQ ’s Keeping tabs on Covid-19 update returns with news from some of the biotechnology innovators leading the fight against the global pandemic.

Vaccine 52

Vaccine Immune Response Government RNA 52

The Pharma Data

MAY 14, 2021

Product Name: Home – Beat Kidney Disease – 2020 – Beat Kidney Disease. Home – Beat Kidney Disease – 2020 – Beat Kidney Disease is backed with a 60 Day No Questions Asked Money Back Guarantee. These statements have not been evaluated by the Food and Drug Administration.

Disease 52

Disease Production Licensing Licensing 52

Broad Institute

MAY 14, 2024

The approach has been used to produce numerous therapeutics, diagnostics, and vaccines — including the COVID-19 mRNA vaccines credited with extending millions of lives in recent years. “F. In 2020, scientists used the T7 platform to produce enough mRNA for COVID-19 vaccines to vaccinate millions of people in the U.S.

RNA 84

RNA Production Molecular Biology Laboratories 84

The Pharma Data

JANUARY 31, 2021

Gilead and Gritstone will develop an HIV-specific therapeutic vaccine using Gritstone’s proprietary prime-boost vaccine platform, comprised of self-amplifying mRNA (SAM) and adenoviral vectors, with antigens developed by Gilead. This press release features multimedia. View the full release here: [link].

Vaccine 52

Vaccine Science Clinical Trials Licensing 52

The Pharma Data

AUGUST 3, 2021

Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areas Fast tracks establishment of Sanofi’s recently announced mRNA Center of Excellence Full integration upgrades drug formulation capabilities and enhances US talent in a promising new technology.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

Drug Channels

OCTOBER 13, 2020

I am pleased to announce our new 2020–21 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. Drug Distribution Industry (press release) We’re offering special discounted pricing if you order before October 23, 2020! healthcare system. There are an astonishing 482 (!)

Pharmaceuticals 52

Pharmaceuticals Licensing Licensing Pharmacy 52

The Pharma Data

APRIL 1, 2021

Sanofi to build new facility in Canada to increase global availability of high-dose influenza vaccine. Sanofi announces investment of more than €600 million to build a new vaccine facility in Toronto to increase supply of its differentiated influenza vaccines in Canada, the United States and Europe.

Vaccine 52

Vaccine Government Science Production 52

The Pharma Data

SEPTEMBER 12, 2020

Food and Drug Administration to expand the enrollment of their Phase 3 pivotal COVID-19 vaccine trial to up to approximately 44,000 participants which also allows for the enrollment of new populations. Pfizer Disclosure Notice: The information contained in this release is as of September 12, 2020. View the full release here: [link].

Vaccine 52

Vaccine Trials Clinical Trials Small Molecule 52

The Pharma Data

JANUARY 9, 2021

Reports preliminary 2020 total revenues of $1.55 billion at the midpoint and Adjusted EBITDA of $635 million at the midpoint, both at or above prior guidance given in November 2020. NYSE:EBS) today announced its financial forecast for 2021 and selected preliminary unaudited financial results for 2020.

Government 52

Government Vaccine Production Licensing 52

The Pharma Data

SEPTEMBER 9, 2020

The proposed agreement is intended to provide a supply of 200 million doses and an option to purchase additional 100 million doses, with deliveries starting by the end of 2020, subject to regulatory approval. Deliveries would be starting by the end of 2020, subject to clinical success and regulatory authorization.

Vaccine 52

Vaccine Clinical Trials Trials Government 52

The Pharma Data

AUGUST 20, 2020

times the GMT of a panel of 38 sera of SARS-CoV-2 convalescent patients, and in older adults (65-85 years of age) the vaccine candidate elicited a neutralizing GMT 1.6 study of the BNT162 mRNA-based vaccine program against SARS-CoV-2, which has advanced into Phase 2/3 evaluation. billion doses by the end of 2021.

Vaccine 52

Vaccine Clinical Trials Trials Immune Response 52

The Pharma Data

SEPTEMBER 9, 2020

The BNT162b2 vaccination also cleared the nose of detectable viral RNA in 100% of the SARS-CoV-2 challenged rhesus macaques within 3 days after the infection. Senior Vice President and Head of Vaccine Research & Development, Pfizer. “We NEW YORK & MAINZ, Germany–(BUSINESS WIRE)– Pfizer Inc. Jansen, Ph.D.,

Vaccine 52

Vaccine RNA Clinical Trials Trials 52

The Pharma Data

JUNE 18, 2021

First approval of a conjugate vaccine that helps protect against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia, 1,2,3,4,5,6,7 including seven responsible for 40% of pneumococcal disease cases and deaths in the U.S. Senior Vice President and Head of Vaccine Research & Development, Pfizer.

Vaccine 52

Vaccine FDA Approval FDA Disease 52

DrugBaron

NOVEMBER 9, 2020

The first death unequivocally caused by COVID was reported to the world on January 11 th 2020 – that’s just 303 days ago (even if it feels like a lifetime away). Indeed, China has already licensed a vaccine, albeit without the data that would typically be required to support such an approval.

Vaccine 100

Vaccine Pharmaceutical Companies Government Pharmaceuticals 100

The Pharma Data

DECEMBER 8, 2020

8, 2020– Moderna, Inc., Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the Swiss Federal Government has increased its confirmed order commitment from 4.5 8, 2020– Moderna, Inc.,

Vaccine 40

Vaccine RNA Clinical Trials Government 40

The Pharma Data

NOVEMBER 9, 2020

NEW YORK & MAINZ, GERMANY–(BUSINESS WIRE) November 9, 2020. Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis. Pfizer Inc. Today is a great day for science and humanity.

Vaccine 40

Vaccine Clinical Trials Trials FDA 40

The Pharma Data

OCTOBER 14, 2020

Study May Lead to Biomarkers for Tailoring COVID-19 Vaccines and Therapeutics. 15, 2020 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. Data from the PRECISION study may help guide research to determine which vaccine or therapeutic is appropriate on an individual basis,” said Seth Lederman, M.D.,

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

The Pharma Data

APRIL 27, 2021

NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they will supply an additional 100 million doses of COMIRNATY®, the companies’ COVID-19 vaccine, to the 27 European Union (EU) member states in 2021. As with any vaccine, vaccination with COMIRNATY® may not protect all vaccine recipients.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

NOVEMBER 29, 2020

Early interim data show Cytomegalovirus (CMV)-negative kidney transplant recipients vaccinated with three doses of HB-101 had reduced incidence of CMV viremia, reduced antiviral use and no CMV disease. 30, 2020 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. . 30, 2020 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc.

Vaccine 52

Vaccine Clinical Trials Disease Therapies 52

The Pharma Data

NOVEMBER 23, 2020

24, 2020 07:05 UTC. OSLO, Norway–( BUSINESS WIRE )– Ultimovacs ASA (“Ultimovacs”, ticker ULTIMO), today announced that Ton Berkien will join Ultimovacs’ management team as Chief Business Officer (CBO), effective December 1, 2020. Berkien is currently a board member of the Nordic Pharma Licensing Group.

Clinical Trials 52

Clinical Trials Small Molecule Pharmaceutical Companies Licensing 52

The Pharma Data

DECEMBER 23, 2020

” Dr. Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” . PLYMOUTH MEETING, Pa. , PLYMOUTH MEETING, Pa. , mg and 2.0

DNA 40

DNA Vaccine Clinical Trials Immune Response 40

The Pharma Data

FEBRUARY 25, 2021

FDA ACCEPTS FOR PRIORITY REVIEW PFIZER’S APPLICATION FOR TICOVAC (TICK-BORNE ENCEPHALITIS VACCINE). If approved, the vaccine may help reduce the risk of TBE for people traveling to endemic areas, potentially including military personnel serving in these locations. 1,2 If approved, TicoVac would be the first vaccine in the U.S.

FDA 52

FDA Vaccine Virus Clinical Trials 52

The Pharma Data

OCTOBER 29, 2020

30, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today new data for baricitinib (marketed as OLUMIANT ® ) will be presented at the annual Fall Clinical Dermatology meeting taking place virtually October 29-November 1, 2020. VACCINATIONS : Avoid use of live vaccines with Olumiant.

Therapies 52

Therapies Treatment Disease Clinical Trials 52

The Pharma Data

DECEMBER 2, 2020

In 2020, the American Cancer Society estimates there to be about 228,280 new cases of lung cancer in the country. Vivlion holds an exclusive license to Goethe University of Frankfurt’s proprietary 3Cs technology for the production of next generation 3Cs CRISPR/Cas gRNA libraries. Horizon Discovery Group – U.K.-based

Licensing 52

Licensing Licensing DNA Vaccine 52

The Pharma Data

AUGUST 22, 2021

AZD7442 is the first antibody combination (non-vaccine) modified to potentially provide long-lasting protection that has demonstrated prevention of COVID-19 in a clinical trial. More than 75% of participants had co-morbidities, which include conditions that have been reported to cause a reduced immune response to vaccination.

Trials 52

Trials Virus Vaccine Pharmacokinetics 52

The Pharma Data

OCTOBER 14, 2020

15, 2020 04:00 UTC. today announced a licensing agreement with MANA Therapeutics for use of its EDIFY platform for the development of an autologous multi-tumor antigen adoptive T cell therapy for the treatment of multiple myeloma and solid tumors, as an additional T cell focused immunotherapeutic for its product pipeline. “Our

Therapies 40

Therapies Licensing Licensing Clinical Trials 40

The Pharma Data

NOVEMBER 5, 2020

PAYSON, UT, November 05, 2020 /24-7PressRelease/ — Dr. Kent R. Van Kampen excels as the chief executive officer of The Van Kampen Group, which assists other companies in research and liaisons with government and industry regarding licensing products for commercial use. Van Kampen has been included in Marquis Who’s Who.

Research 52

Research Vaccine Doctors Pharmaceuticals 52

The Pharma Data

JANUARY 5, 2021

Besides giving telemedicine a boost, the pandemic has also fostered the rise of innovative medical services, everything from getting prescriptions by mail to drive-through virus testing and pharmacy-based vaccinations. But from March through May of 2020 they jumped to 3,000 to 4,000 visits per day, Keeves said.

Doctors 52

Doctors Pharmacy Vaccine Licensing 52

Drug Channels

OCTOBER 19, 2020

December 1-3, 2020 | Virtual Event www.informaconnect.com/trade-channel. Get ready to hit the ground running in 2021 by closing out the year at Trade and Channel 2020 ! Copyright © 2006-2020 Pembroke Consulting, Inc. 16th Annual Life Sciences Trade and Channel Strategies. Other restrictions may apply.

Specialty Pharmacies 52

Specialty Pharmacies Science Pharmacy Licensing 52

The Pharma Data

APRIL 27, 2021

at CER driven by growth drivers Dupixent ® and Vaccines. Vaccines up 5.3%, driven by PPH franchise and demand for influenza vaccines in southern hemisphere. due to COVID related stocking in Q1 2020 and low demand for cough and cold brands in Europe. Vaccines delivered growth in its core segments.

Vaccine 52

Vaccine Production FDA Disease 52